Thymosin Alpha 1 is strictly for laboratory research and is commonly employed in the following investigational areas:

Infectious Disease and Sepsis Models

Researchers utilize Thymosin Alpha 1 to investigate its capacity to modulate immune function in severe sepsis. Studies focus on evaluating its potential as an immunotherapy to improve immune responses in aged models and its efficacy in mitigating viral-induced cytokine storms, such as those seen in SARS-CoV-2 and Hepatitis C models.

Oncology and Adjuvant Therapy

In experimental oncology, this peptide is employed to study its anti-tumor effects and synergistic potential when combined with standard chemotherapies. Investigations evaluate its use as an adjuvant in models of melanoma, nasal natural killer/T-cell lymphoma, and peritoneal metastases from colonic carcinoma.

Autoimmunity and Inflammation

Experimental protocols use Thymosin Alpha 1 to characterize its biological activities in chronic inflammatory autoimmune diseases and arthritis. Furthermore, it is investigated for its ability to inhibit complete Freund’s adjuvant-induced pain by suppressing the production of microglia-mediated pro-inflammatory cytokines in spinal cord models.

Vaccine Immunogenicity and Extrapulmonary Research

Studies utilize this peptide to evaluate its role in enhancing the immunogenicity of specific vaccines, such as the pandemic H1N1 influenza vaccine, particularly in immunocompromised models. Additionally, it is investigated for its beneficial extrapulmonary effects in complex conditions like cystic fibrosis.

Pathway / Mechanistic Context

The primary mechanism of action for Thymosin Alpha 1 in research settings involves its broad function as an immunomodulator and a stimulatory agent of the innate cell-mediated immune response.

• Cytokine Modulation: Mitigates severe inflammatory responses, such as cytokine storms, by regulating the output of immune cells in viral and septic models.
• Immune Cell Stimulation: Enhances the activity and efficacy of innate immune cells, exhibiting anti-tumor effects in specific lymphoma and carcinoma models.
• Neuroinflammatory Inhibition: Suppresses the production of pro-inflammatory cytokines mediated by microglia, which correlates with the inhibition of induced pain pathways in the spinal cord.

Preclinical Research Summary

Published preclinical and clinical-translational literature documents the extensive investigation of Thymosin Alpha 1 across diverse experimental models of infection, oncology, and inflammation.

• In oncology models, combining Thymosin Alpha 1 with gemcitabine exhibited enhanced anti-tumor effects against nasal natural killer/T-cell lymphoma.
• Research on viral immunology demonstrated that the peptide effectively mitigated cytokine storms in blood cells derived from COVID-19 patients.
• In neurological and pain models, Thymosin Alpha 1 inhibited pain induced by complete Freund’s adjuvant and reduced microglia-mediated pro-inflammatory cytokines in the spinal cord.
• Studies on severe sepsis indicate that Thymosin Alpha 1 treatment can serve as a potent immunotherapy to support immune function, particularly in aged subjects.

Form & Analytical Testing

• Solid-Phase Peptide Synthesis or Genetic Engineering Production
• Lyophilization
• Identity Verification: Mass Spectrometry (MS) to confirm molecular weight and identity.
• Purity Verification: High-Performance Liquid Chromatography (HPLC) is performed to ensure the product meets the purity standard.

Referenced Citations

References are provided for informational purposes only and are not clinical claims.

• Matteucci, C., et al. (2020). Thymosin alpha 1 mitigates cytokine storm in blood cells from coronavirus disease 2019 patients. Open Forum Infectious Diseases, 8(1). https://doi.org/10.1093/ofid/ofaa588
• Chen, M., et al. (2021). Combination of gemcitabine and thymosin alpha 1 exhibit a better anti-tumor effect on nasal natural killer/t-cell lymphoma. International Immunopharmacology, 98, 107829. https://doi.org/10.1016/j.intimp.2021.107829
• Wu, J., et al. (2013). The efficacy of thymosin alpha 1 for severe sepsis (etass): a multicenter, single-blind, randomized and controlled trial. Critical Care, 17(1). https://doi.org/10.1186/cc11932
• Serafino, A., et al. (2012). Thymosin α1 as a stimulatory agent of innate cell‐mediated immune response. Annals of the New York Academy of Sciences, 1270(1), 13-20. https://doi.org/10.1111/j.1749-6632.2012.06707.x
• Xu, Y., et al. (2019). Thymosin alpha-1 inhibits complete freund’s adjuvant-induced pain and production of microglia-mediated pro-inflammatory cytokines in spinal cord. Neuroscience Bulletin, 35(4), 637-648. https://doi.org/10.1007/s12264-019-00346-z

• Stable at room temperature for up to 90 days. For long-term storage, keep at -20°C (-4°F) or colder.
• Once mixed with a solvent (e.g., bacteriostatic water), the solution must be stored at 4 °C (39°F) and utilized within 30 days. Avoid repeated freeze-thaw cycles, as this degrades the peptide structure.

RESEARCH USE ONLY

This product is intended strictly for laboratory research use only. It is not for human or veterinary use. It is not intended for diagnosis, treatment, cure, or prevention of any disease. All purchases are subject to our Terms of Service and Purity Guarantee.

No COAs available for this product.